A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells in solid tumors.
Manon VounckxJens TijtgatLatoya StevensIris DirvenBart IlsenFrederik VandenbrouckeSteven RaeymaeckersKarolien VekensRamses ForsythXenia GeeraertsIvan Van RietJulia Katharina SchwarzeSandra TuyaertsLore DecosterMark De RidderInes DufaitBart NeynsPublished in: Cancer immunology, immunotherapy : CII (2024)
2019-003668-32. Date of registration: 17 DEC 2019, amendment 1: 6 MAR 2021, amendment 2: 4 FEB 2022.